Molecule profile · Module 6
GHK-Cu — evidence and research limits
This label describes the research context of this profile, not a product-by-product approval determination. It does not mean every use of the molecule lacks approval. Read the existing evidence details and regulatory context for the specific preparation, indication and jurisdiction; no new approval is inferred.
MOLECULE PROFILE
- Evidence summary
- Investigational — profile context
- The references include fibroblast experiments, rat wound models, and a human trial of a topical preparation for diabetic ulcers. They answer different questions and do not establish a subcutaneous regimen. GHK-Cu and AHK-Cu are different peptides; shared copper binding does not make their evidence interchangeable. The interpretation is specific to the studied molecule, formulation, route, population, and endpoint. Reported commercial regimens are not validated by a study of a different product or outcome.
- Regulatory status varies by jurisdiction
- The academic source does not establish a current authorization for every preparation sold under this name. Product identity, formulation, indication, jurisdiction, and current official labeling must be checked separately. A discussion of compounding or an advisory meeting is not a product approval.
Educational information for healthcare professionals and the general public. Not individual medical advice, diagnosis, treatment, or a recommendation to use a compound.
Identity and mechanism
GHK-Cu is a copper-binding tripeptide complex studied in extracellular-matrix biology. The course distinguishes fibroblast experiments, animal wound models, and a historical topical human trial. A change in matrix synthesis is not the same as a demonstrated systemic repair treatment. GHK-Cu and AHK-Cu also need separate identification.
What the evidence supports
The references include fibroblast experiments, rat wound models, and a human trial of a topical preparation for diabetic ulcers. They answer different questions and do not establish a subcutaneous regimen. GHK-Cu and AHK-Cu are different peptides; shared copper binding does not make their evidence interchangeable.
The interpretation is specific to the studied molecule, formulation, route, population, and endpoint. Reported commercial regimens are not validated by a study of a different product or outcome.
Regulatory context
The academic source does not establish a current authorization for every preparation sold under this name. Product identity, formulation, indication, jurisdiction, and current official labeling must be checked separately. A discussion of compounding or an advisory meeting is not a product approval.
Safety and uncertainty
Topical tolerability does not determine subcutaneous safety. Distinguish irritation/reactions from a specific formulation from systemic risks not yet characterized by these references. Human safety cannot be inferred from a cell result, a product name, or lack of events in a small report. These educational adaptations do not provide an administration protocol.
Continue learning
Explore Module 6 in PEPTIDE Academy for the full evidence discussion.
Product, route and measured result
A topical preparation and an injectable preparation are different interventions, even when their names include the same peptide. Record the complete formulation, vehicle, route and measured outcome before comparing reports. A change in a collagen-related measurement is not automatically a change in appearance, function or a symptom important to a patient.
When photographs are used, check whether lighting, camera position, expression, timing and concurrent care were standardized. A vehicle control and blinded assessment help answer different questions from an uncontrolled before-and-after image. An AI-generated illustration may explain a concept if labeled, but it cannot serve as a patient result or evidence of efficacy.
References
Bibliographic sources shown for transparency. Citation verification pending; no citation is marked verified.
- Maquart FX, Bellon G, Chaqour B, et al. In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds. J Clin Invest. 1993;92(5):2368-76. DOI: 10.1172/JCI116842. PMID: 8227353.DOI 10.1172/JCI116842 · PMID 8227353
- Wegrowski Y, Maquart FX, Borel JP. Stimulation of sulfated glycosaminoglycan synthesis by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. Life Sci. 1992;51(13):1049-56. DOI: 10.1016/0024-3205(92)90504-i. PMID: 1522753.DOI 10.1016/0024-3205(92)90504-i · PMID 1522753
- Mulder GD, Patt LM, Sanders L, et al. Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper. Wound Repair Regen. 1994;2(4):259-69. DOI: 10.1046/j.1524-475X.1994.20406.x. PMID: 17147644.DOI 10.1046/j.1524-475X.1994.20406.x · PMID 17147644
Related resources
Molecule profile · Module 6
BPC-157
BPC-157 has been investigated in experimental tissue-repair models. The course examines tendon-cell survival, migration, and growth from explants as mechanistic findings. Those endpoints can help formulate hypotheses about repair; they do not directly measure recovery from a human tendon injury or return to sport.
Molecule profile · Module 6
TB-500 and thymosin beta-4
Full-length thymosin beta-4 participates in actin-related cellular biology. The name TB-500 has also been used for a characterized acetylated fragment; it does not reliably identify every product sold under that name. Analytical identity, full-length peptide studies, and fragment studies must remain separate before discussing repair mechanisms or clinical effects.
Molecule profile · Module 3
AOD-9604
AOD-9604 is a modified fragment related to the C-terminal region of growth hormone. The rationale discussed in the course concerns metabolic effects attributed to the fragment, rather than assuming that it reproduces every action of full-length growth hormone. Identity, formulation, and route must be specified when comparing reports.